Peptide Nucleic Acids as Epigenetic Inhibitors of HIV-1

  • Shizuko Sei
Part of the Medical Intelligence Unit book series (MIUN)


Human Immunodeficiency Virus Human Immunodeficiency Virus Type Human Immunodeficiency Virus Infection Acquire Immune Deficiency Syndrome Peptide Nucleic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Masur H, Michelis MA, Greene JB et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: Initial manifestation of cellular immune dysfunction. N Engl J Med 1981; 305:1431–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Gottlieb MS, Schroff R, Schanker HM et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981; 305:1425–31.PubMedCrossRefGoogle Scholar
  3. 3.
    Division of HIV/AIDS Prevention National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Vol. 10. Department of Health and Human Services. Atlanta, US: Public Health Service, 1998:1–40.Google Scholar
  4. 4.
    Aalen OO, Farewell VT, De Angelis D et al. New therapy explains the fall in AIDS incidence with a substantial rise in number of persons on treatment expected. AIDS 1999; 13:103–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Boden D, Hurley A, Zhang L et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999; 282:1135–41.PubMedCrossRefGoogle Scholar
  6. 6.
    Little SJ, Daar ES, D’Aquila RT et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999; 282:1142–9.PubMedCrossRefGoogle Scholar
  7. 7.
    UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001; 322:1087–8.CrossRefGoogle Scholar
  8. 8.
    Larder BA, Hertogs K, Bloor S et al. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000; 14:1943–8.PubMedCrossRefGoogle Scholar
  9. 9.
    For a detailed review on HIV-1 and its replication cycle see; Human immunodeficiency viruses and their replication. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2001.Google Scholar
  10. 10.
    Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17:657–700.PubMedCrossRefGoogle Scholar
  11. 11.
    Kaplan AH, Manchester M, Swanstrom R. The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J Virol 1994; 68:6782–6.PubMedGoogle Scholar
  12. 12.
    Mitsuya H, Weinhold KJ, Furman PA et al. 3′-Azido-3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985; 82:7096–100.PubMedCrossRefGoogle Scholar
  13. 13.
    Yarchoan R, Klecker RW, Weinhold KJ et al. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986; 1:575–80.PubMedCrossRefGoogle Scholar
  14. 14.
    Mitsuya H, Jarrett RF, Matsukura M et al. Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2′,3′-dideoxynucleosides in vitro. Proc Natl Acad Sci USA 1987; 84:2033–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Yarchoan R, Mitsuya H, Thomas RV et al. In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine. Science 1989; 245:412–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Oberlin E, Amara A, Bachelerie F et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 [published erratum appears in Nature 1996 Nov 21;384(6606):288]. Nature 1996; 382:833–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Doranz BJ, Grovit-Ferbas K, Sharron MP et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 1997; 186:1395–400.PubMedCrossRefGoogle Scholar
  18. 18.
    Murakami T, Nakajima T, Koyanagi Y et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 1997; 186:1389–93.PubMedCrossRefGoogle Scholar
  19. 19.
    Simmons G, Clapham PR, Picard L et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997; 276:276–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Donzella GA, Schols D, Lin SW et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 coreceptor. Nat Med 1998; 4:72–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Gong W, Howard OM, Turpin JA et al. Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication. J Biol Chem 1998; 273:4289–92.PubMedCrossRefGoogle Scholar
  22. 22.
    Kilby JM, Hopkins S, Venetta TM et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4:1302–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Pilcher CD, Eron Jr JJ, Ngo L et al. Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual. AIDS 1999; 13:2171–3.PubMedCrossRefGoogle Scholar
  24. 24.
    Puras Lutzke RA, Eppens NA, Weber PA et al. Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library. Proc Natl Acad Sci USA 1995; 92:11456–60.PubMedCrossRefGoogle Scholar
  25. 25.
    Eich E, Pertz H, Kaloga M et al. (-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase. J Med Chem 1996; 39:86–95.PubMedCrossRefGoogle Scholar
  26. 26.
    Mazumder A, Neamati N, Ojwang JO et al. Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry 1996; 35:13762–71.PubMedCrossRefGoogle Scholar
  27. 27.
    Zhao H, Neamati N, Hong H et al. Coumarin-based inhibitors of HIV integrase. J Med Chem 1997; 40:242–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Zhao H, Neamati N, Sunder S et al. Hydrazide-containing inhibitors of HIV-1 integrase. J Med Chem 1997; 40:937–41.PubMedCrossRefGoogle Scholar
  29. 29.
    Artico M, Di Santo R, Costi R et al. Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: Synthesis, biological evaluation, and molecular modeling. J Med Chem 1998; 41:3948–60.PubMedCrossRefGoogle Scholar
  30. 30.
    Farnet CM, Wang B, Hansen M et al. Human immunodeficiency virus type 1 cDNA integration: New aromatic hydroxylated inhibitors and studies of the inhibition mechanism. Antimicrob Agents Chemother 1998; 42:2245–53.PubMedGoogle Scholar
  31. 31.
    Neamati N, Hong H, Owen JM et al. Salicylhydrazine-containing inhibitors of HIV-1 integrase: Implication for a selective chelation in the integrase active site. J Med Chem 1998; 41:3202–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Molteni V, Rhodes D, Rubins K et al. A new class of HIV-1 integrase inhibitors: The 3,3,3′, 3′-tetramethyl-1′-spirobi(indan)-5,5′,6,6′-tetrol family. J Med Chem 2000; 43:2031–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Reddy MV, Rao MR, Rhodes D et al. Lamellarin alpha 20-sulfate, an inhibitor of HIV-1 integrase active against HIV-1 virus in cell culture. J Med Chem 1999; 42:1901–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Hazuda DJ, Felock P, Witmer M et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287:646–50.PubMedCrossRefGoogle Scholar
  35. 35.
    Rice WG, Schaeffer CA, Harten B et al. Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds. Nature 1993; 361:473–5.PubMedCrossRefGoogle Scholar
  36. 36.
    McDonnell NB, De Guzman RN, Rice WG et al. Zinc ejection as a new rationale for the use of cystamine and related disulfide-containing antiviral agents in the treatment of AIDS. J Med Chem 1997; 40:1969–76.PubMedCrossRefGoogle Scholar
  37. 37.
    Rice WG, Baker DC, Schaeffer CA et al. Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Antimicrob Agents Chemother 1997; 41:419–26.PubMedGoogle Scholar
  38. 38.
    Haubrich RH, Flexner C, Lederman MM et al. A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J Infect Dis 1995; 172:1246–52.PubMedGoogle Scholar
  39. 39.
    Dropulic B, Jeang KT. Gene therapy for human immunodeficiency virus infection: Genetic antiviral strategies and targets for intervention. Hum Gene Ther 1994; 5:927–39.PubMedGoogle Scholar
  40. 40.
    Morgan RA. Genetic strategies to inhibit HIV. Mol Med Today 1999; 5:454–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Dornburg R, Pomerantz RJ. HIV-1 gene therapy: Promise for the future. Adv Pharmacol 2000; 49:229–61.PubMedCrossRefGoogle Scholar
  42. 42.
    Zamecnik PC, Goodchild J, Taguchi Y et al. Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc Natl Acad Sci USA 1986; 83:4143–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Matsukura M, Zon G, Shinozuka K et al. Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci USA 1989; 86:4244–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Agrawal S, Ikeuchi T, Sun D et al. Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues. Proc Natl Acad Sci USA 1989; 86:7790–4.PubMedCrossRefGoogle Scholar
  45. 45.
    Kinchington D, Galpin S, Jaroszewski JW et al. A comparison of gag, pol and rev antisense oligodeoxynucleotides as inhibitors of HIV-1. Antiviral Res 1992; 17:53–62.PubMedCrossRefGoogle Scholar
  46. 46.
    Lisziewicz J, Sun D, Klotman M et al. Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: An in vitro model for treatment. Proc Natl Acad Sci USA 1992; 89:11209–13.PubMedCrossRefGoogle Scholar
  47. 47.
    Lisziewicz J, Sun D, Metelev V, Zamecnik P et al. Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates. Proc Natl Acad Sci USA 1993; 90:3860–4.PubMedCrossRefGoogle Scholar
  48. 48.
    Lisziewicz J, Sun D, Weichold FF et al. Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proc Natl Acad Sci USA 1994; 91:7942–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Anazodo MI, Wainberg MA, Friesen AD et al. Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type 1 genome. J Virol 1995; 69:1794–801.PubMedGoogle Scholar
  50. 50.
    Lisziewicz J, Sun D, Lisziewicz A et al. Antitat gene therapy: A candidate for late-stage AIDS patients. Gene Ther 1995; 2:218–22.PubMedGoogle Scholar
  51. 51.
    Kim SG, Hatta T, Tsukahara S et al. Antiviral effect of phosphorothioate oligodeoxyribonucleotides complementary to human immunodeficiency virus. Bioorg Med Chem 1995; 3:49–54.PubMedCrossRefGoogle Scholar
  52. 52.
    Weichold FF, Lisziewicz J, Zeman RA et al. Antisense phosphorothioate oligodeoxynucleotides alter HIV type 1 replication in cultured human macrophages and peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 1995; 11:863–7.PubMedGoogle Scholar
  53. 53.
    Anazodo MI, Duta E, Friesen AD et al. Relative levels of inhibition of p24 gene expression by different 20-mer antisense oligonucleotide sequences targeting nudeotides + 1129 to + 1268 of the HIV-1 gag genome: An analysis of mechanism. Biochem Biophys Res Commun 1996; 229:305–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Yamaguchi K, Papp B, Zhang D et al. The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1997; 13:545–54.PubMedCrossRefGoogle Scholar
  55. 55.
    Clinical trial results of GEM91 show activity against advance HIV. AIDS Patient Care STDS 1997; 11:290–1.Google Scholar
  56. 56.
    Stoddart CA, Rabin L, Hincenbergs M et al. Inhibition of human immunodeficiency virus type 1 infection in SCID-hu Thy/Liv mice by the G-quartet-forming oligonucleotide, ISIS 5320. Antimicrob Agents Chemother 1998; 42:2113–5.PubMedGoogle Scholar
  57. 57.
    Temsamani J, Roskey A, Chaix C et al. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide. Antisense Nucleic Acid Drug Dev 1997; 7:159–65.PubMedGoogle Scholar
  58. 58.
    Baker BF, Monia BP. Novel mechanisms for antisense-mediated regulation of gene expression. Biochim Biophys Acta 1999; 1489:3–18.PubMedGoogle Scholar
  59. 59.
    Wang S, Dolnick BJ. Quantitative evaluation of intracellular sense: Antisense RNA hybrid duplexes. Nucleic Acids Res 1993; 21:4383–91.PubMedCrossRefGoogle Scholar
  60. 60.
    Too CK. Rapid induction of Jak2 and Sp1 in T cells by phosphorothioate oligonucleotides. Antisense Nucleic Acid Drug Dev 1998; 8:87–94.PubMedGoogle Scholar
  61. 61.
    Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995; 69:5087–94.PubMedGoogle Scholar
  62. 62.
    Patel PH, Preston BD. Marked infidelity of human immunodeficiency virus type 1 reverse transcriptase at RNA and DNA template ends. Proc Natl Acad Sci USA 1994; 91:549–53.PubMedCrossRefGoogle Scholar
  63. 63.
    Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science 1988; 242:1168–71.PubMedCrossRefGoogle Scholar
  64. 64.
    Perelson AS, Neumann AU, Markowitz M et al. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582–6.PubMedCrossRefGoogle Scholar
  65. 65.
    Goodenow M, Huet T, Saurin W et al. HIV-1 isolates are rapidly evolving quasispecies: Evidence for viral mixtures and preferred nucleotide substitutions. J Acquir Immune Defic Syndr 1989; 2:344–52.PubMedGoogle Scholar
  66. 66.
    Hermankova M, Ray SC, Ruff C et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA 2001; 286:196–207.PubMedCrossRefGoogle Scholar
  67. 67.
    Nielsen PE, Egholm M, Berg RH et al. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 1991; 254:1497–500.PubMedCrossRefGoogle Scholar
  68. 68.
    Hanvey JC, Peffer NJ, Bisi JE et al. Antisense and antigene properties of peptide nucleic acids. Science 1992; 258:1481–5.PubMedCrossRefGoogle Scholar
  69. 69.
    Egholm M, Buchardt O, Christensen L et al. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules [see comments]. Nature 1993; 365:566–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Wittung P, Nielsen PE, Buchardt O et al. DNA-like double helix formed by peptide nucleic acid. Nature 1994; 368:561–3.PubMedCrossRefGoogle Scholar
  71. 71.
    Demidov W, Potaman VN, Frank-Kamenetskii MD et al. Stability of peptide nucleic acids in human serum and cellular extracts. Biochem Pharmacol 1994; 48:1310–3.PubMedCrossRefGoogle Scholar
  72. 72.
    Egholm M, Buchardt O, Nielsen PE et al. Peptide nucleic acids (PNA). Oligonucleotide analogues with an achiral peptide backbone. J Am Chem Soc 1992; 114:1895–7.CrossRefGoogle Scholar
  73. 73.
    Igloi GL. Variability in the stability of DNA-peptide nucleic acid (PNA) single-base mismatched duplexes: Real-time hybridization during affinity electrophoresis in PNA-containing gels. Proc Natl Acad Sci USA 1998; 95:8562–7.PubMedCrossRefGoogle Scholar
  74. 74.
    Wittung P, Kajanus J, Edwards K et al. Phospholipid membrane permeability of peptide nucleic acid [corrected and republished with original paging, article originally printed in FEBS Lett 1995 May 22;365(1):27–9]. FEBS Lett 1995; 375:27–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Noble SA, Bonham MA, Bisi JE et al. Impact of biophysical parameters on the biological assessment of peptide nucleic acids, antisense inhibitors of gene expression. Drug Development Research 1995; 34:184–95.CrossRefGoogle Scholar
  76. 76.
    Chinnery PF, Taylor RW, Diekert K et al. Peptide nucleic acid delivery to human mitochondria. Gene Ther 1999; 6:1919–28.PubMedCrossRefGoogle Scholar
  77. 77.
    Gray GD, Basu S, Wickstrom E. Transformed and immortalized cellular uptake of oligodeoxynucleoside phosphorothioates, 3′-alkylamino oligodeoxynucleotides, 2′-O-methyl oligoribonucleotides, oligodeoxynucleoside methylphosphonates, and peptide nucleic acids. Biochem Pharmacol 1997; 53:1465–76.PubMedCrossRefGoogle Scholar
  78. 78.
    Sei S, Yang QE, O’Neill D et al. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J Virol 2000; 74:4621–33.PubMedCrossRefGoogle Scholar
  79. 79.
    Fraser GL, Holmgren J, Clarke PB et al. Antisense inhibition of delta-opioid receptor gene function in vivo by peptide nucleic acids. Mol Pharmacol 2000; 57:725–31.PubMedGoogle Scholar
  80. 80.
    Tyler BM, Jansen K, McCormick DJ et al. Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression. Proc Natl Acad Sci USA 1999; 96:7053–8.PubMedCrossRefGoogle Scholar
  81. 81.
    Bonham MA, Brown S, Boyd AL et al. An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers. Nucleic Acids Res 1995; 23:1197–203.PubMedCrossRefGoogle Scholar
  82. 82.
    Shammas MA, Simmons CG, Corey DR et al. Telomerase inhibition by peptide nucleic acids reverses ‘immortality’ of transformed human cells. Oncogene 1999; 18:6191–200.PubMedCrossRefGoogle Scholar
  83. 83.
    Wang G, Xu X, Pace B et al. Peptide nucleic acid (PNA) binding-mediated induction of human gamma-globin gene expression. Nucleic Acids Res 1999; 27:2806–13.PubMedCrossRefGoogle Scholar
  84. 84.
    Mayhood T, Kaushik N, Pandey PK et al. Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element. Biochemistry 2000; 39:11532–9.PubMedCrossRefGoogle Scholar
  85. 85.
    Gottlinger HG, Dorfman T, Sodroski JG et al. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci USA 1991; 88:3195–9.PubMedCrossRefGoogle Scholar
  86. 86.
    Huang M, Orenstein JM, Martin MA et al. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol 1995; 69:6810–8.PubMedGoogle Scholar
  87. 87.
    Yu XF, Dawson L, Tian CJ et al. Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly. J Virol 1998; 72:3412–7PubMedGoogle Scholar
  88. 88.
    Jacks T, Varmus HE. Expression of the Rous sarcoma virus pol gene by ribosomal frameshifting. Science 1985; 230:1237–42.PubMedCrossRefGoogle Scholar
  89. 89.
    Hizi A, Henderson LE, Copeland TD et al. Characterization of mouse mammary tumor virus gag-pro gene products and the ribosomal frameshift site by protein sequencing. Proc Natl Acad Sci USA 1987; 84:7041–5.PubMedCrossRefGoogle Scholar
  90. 90.
    Jacks T, Townsley K, Varmus HE et al. Two efficient ribosomal frameshifting events are required for synthesis of mouse mammary tumor virus gag-related polyproteins. Proc Natl Acad Sci USA 1987; 84:4298–302.PubMedCrossRefGoogle Scholar
  91. 91.
    Mador N, Panet A, Honigman A. Translation of gag, pro, and pol gene products of human T-cell leukemia virus type 2. J Virol 1989; 63:2400–4.PubMedGoogle Scholar
  92. 92.
    Nam SH, Copeland TD, Hatanaka M et al. Characterization of ribosomal frameshifting for expression of pol gene products of human T-cell leukemia virus type I. J Virol 1993; 67:196–203.PubMedGoogle Scholar
  93. 93.
    Jacks T, Power MD, Masiarz FR et al. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 1988; 331:280–3.PubMedCrossRefGoogle Scholar
  94. 94.
    Wilson W, Braddock M, Adams SE et al. HIV expression strategies: Ribosomal frameshifting is directed by a short sequence in both mammalian and yeast systems. Cell 1988; 55:1159–69.PubMedCrossRefGoogle Scholar
  95. 95.
    Kozal MJ, Shah N, Shen N et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996; 2:753–9.PubMedCrossRefGoogle Scholar
  96. 96.
    Lech WJ, Wang G, Yang YL et al. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: Presence of protease inhibitor-resistant variants in untreated subjects. J Virol 1996; 70:2038–43.PubMedGoogle Scholar
  97. 97.
    Barrie KA, Perez EE, Lamers SL et al. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: Amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. Virology 1996; 219:407–16.PubMedCrossRefGoogle Scholar
  98. 98.
    Checroune F, Yao XJ, Gottlinger HG et al. Incorporation of Vpr into human immunodeficiency virus type 1: Role of conserved regions within the P6 domain of Pr55gag. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:1–7.PubMedCrossRefGoogle Scholar
  99. 99.
    Lu YL, Bennett RP, Wills JW et al. A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virol 1995; 69:6873–9.PubMedGoogle Scholar
  100. 100.
    Kondo E, Gottlinger HG. A conserved LXXLF sequence is the major determinant in p6gag required for the incorporation of human immunodeficiency virus type 1 Vpr. J Virol 1996; 70:159–64.PubMedGoogle Scholar
  101. 101.
    Yoshimura K, Kato R, Yusa K et al. JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc Natl Acad Sci USA 1999; 96:8675–80.PubMedCrossRefGoogle Scholar
  102. 102.
    Pearl LH, Taylor WR. A structural model for the retroviral proteases. Nature 1987; 329:351–4.PubMedCrossRefGoogle Scholar
  103. 103.
    Wlodawer A, Miller M, Jaskolski M et al. Conserved folding in retroviral proteases: Crystal structure of a synthetic HIV-1 protease. Science 1989; 245:616–21.PubMedCrossRefGoogle Scholar
  104. 104.
    Strickler JE, Gorniak J, Dayton B et al. Characterization and autoprocessing of precursor and mature forms of human immunodeficiency virus type 1 (HIV 1) protease purified from Escherichia coli. Proteins 1989; 6:139–54.PubMedCrossRefGoogle Scholar
  105. 105.
    Rose JR, Salto R, Craik CS. Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions. J Biol Chem 1993; 268:11939–45.PubMedGoogle Scholar
  106. 106.
    Park J, Morrow CD. The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into viruslike particles. J Virol 1992; 66:6304–13.PubMedGoogle Scholar
  107. 107.
    Smith AJ, Srinivasakumar N, Hammarskjold ML et al. Requirements for incorporation of Pr160gag-pol from human immunodeficiency virus type 1 into virus-like particles. J Virol 1993; 67:2266–75.PubMedGoogle Scholar
  108. 108.
    Lee YM, Yu XF. Identification and characterization of virus assembly intermediate complexes in HIV-1-infected CD4+ T cells. Virology 1998; 243:78–93.PubMedCrossRefGoogle Scholar
  109. 109.
    Lee YM, Tian CJ, Yu XF. A bipartite membrane-binding signal in the human immunodeficiency virus type 1 matrix protein is required for the proteolytic processing of Gag precursors in a cell type-dependent manner. J Virol 1998; 72:9061–8.PubMedGoogle Scholar
  110. 110.
    Rhee SS, Hunter E. Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids. J Virol 1987; 61:1045–53.PubMedGoogle Scholar
  111. 111.
    Gottlinger HG, Sodroski JG, Haseltine WA. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1989; 86:5781–5.PubMedCrossRefGoogle Scholar
  112. 112.
    Bryant M, Ratner L. Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci USA 1990; 87:523–7.PubMedCrossRefGoogle Scholar
  113. 113.
    Park J, Morrow CD. Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production. J Virol 1991; 65:5111–7.PubMedGoogle Scholar
  114. 114.
    Karacostas V, Wolffe EJ, Nagashima K et al. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology 1993; 193:661–71.PubMedCrossRefGoogle Scholar
  115. 115.
    Koppelhus U, Zachar V, Nielsen PE et al. Efficient in vitro inhibition of HIV-1 gag reverse transcription by peptide nucleic acid (PNA) at minimal ratios of PNA/RNA. Nucleic Acids Res 1997; 25:2167–73.PubMedCrossRefGoogle Scholar
  116. 116.
    Boulme F, Freund F, Moreau S et al. Modified (PNA, 2′-O-methyl and phosphoramidate) anti-TAR antisense oligonucleotides as strong and specific inhibitors of in vitro HIV-1 reverse transcription. Nucleic Acids Res 1998; 26:5492–500.PubMedCrossRefGoogle Scholar
  117. 117.
    Lee R, Kaushik N, Modak MJ et al. Polyamide nucleic acid targeted to the primer binding site of the HIV-1 RNA genome blocks in vitro HIV-1 reverse transcription. Biochemistry 1998; 37:900–10.PubMedCrossRefGoogle Scholar
  118. 118.
    Mischiati C, Borgatti M, Bianchi N et al. Interaction of the human NF-kappaB p52 transcription factor with DNA-PNA hybrids mimicking the NF-kappaB binding sites of the human immuno-deficiency virus type 1 promoter. J Biol Chem 1999; 274:33114–22.PubMedCrossRefGoogle Scholar
  119. 119.
    Danner SA, Carr A, Leonard JM et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995; 333:1528–33.PubMedCrossRefGoogle Scholar
  120. 120.
    Markowitz M, Saag M, Powderly WG et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995; 333:1534–9.PubMedCrossRefGoogle Scholar
  121. 121.
    Collier AC, Coombs RW, Schoenfeld DA et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996; 334:1011–7.PubMedCrossRefGoogle Scholar
  122. 122.
    Schapiro JM, Winters MA, Stewart F et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients [see comments]. Ann Intern Med 1996; 124:1039–50.PubMedGoogle Scholar
  123. 123.
    Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team [see comments]. N Engl J Med 1997; 337:725–33.PubMedCrossRefGoogle Scholar
  124. 124.
    Gulick RM, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy [see comments]. N Engl J Med 1997; 337:734–9.PubMedCrossRefGoogle Scholar
  125. 125.
    Summerton J. Morpholino antisense oligomers: The case for an RNase H-independent structural type. Biochim Biophys Acta 1999; 1489:141–58.PubMedGoogle Scholar
  126. 126.
    Stein D, Foster E, Huang SB et al. A specificity comparison of four antisense types: Morpholino, 2′-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev 1997; 7:151–7.PubMedGoogle Scholar
  127. 127.
    Summerton J, Stein D, Huang SB et al. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev 1997; 7:63–70.PubMedGoogle Scholar
  128. 128.
    Knudsen H, Nielsen PE. Antisense properties of duplex-and triplex-forming PNAs. Nucleic Acids Res 1996; 24:494–500.PubMedCrossRefGoogle Scholar
  129. 129.
    Gambacorti-Passerini C, Mologni L, Bertazzoli C et al. In vitro transcription and translation inhibition by anti-promyelocytic leukemia (PML)/retinoic acid receptor alpha and anti-PML peptide nucleic acid. Blood 1996; 88:1411–7.PubMedGoogle Scholar
  130. 130.
    Mologni L, Marchesi E, Nielsen PE et al. Inhibition of promyelocytic leukemia (pml)/retinoic acid receptor-alpha and pml expression in acute promyelocytic leukemia cells by anti-pml peptide nucleic acid. Cancer Res 2001; 61:5468–73.PubMedGoogle Scholar
  131. 131.
    Pooga M, Soomets U, Hallbrink M et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol 1998; 16:857–61.PubMedCrossRefGoogle Scholar
  132. 132.
    Scarfi S, Giovine M, Gasparini A et al. Modified peptide nucleic acids are internalized in mouse macrophages RAW 264.7 and inhibit inducible nitric oxide synthase. FEBS Lett 1999; 451:264–8.PubMedCrossRefGoogle Scholar
  133. 133.
    Dias N, Dheur S, Nielsen PE et al. Antisense PNA tridecamers targeted to the coding region of Ha-ras mRNA arrest polypeptide chain elongation. J Mol Biol 1999; 294:403–16.PubMedCrossRefGoogle Scholar
  134. 134.
    Brown SC, Thomson SA, Veal JM et al. NMR solution structure of a peptide nucleic acid complexed with RNA. Science 1994; 265:777–80.PubMedCrossRefGoogle Scholar
  135. 135.
    Betts L, Josey JA, Veal JM et al. A nucleic acid triple helix formed by a peptide nucleic acid-DNA complex. Science 1995; 270:1838–41.PubMedCrossRefGoogle Scholar
  136. 136.
    Eriksson M, Nielsen PE. Solution structure of a peptide nucleic acid-DNA duplex. Nat Struct Biol 1996; 3:410–3.PubMedCrossRefGoogle Scholar
  137. 137.
    Rasmussen H, Kastrup JS, Nielsen JN et al. Crystal structure of a peptide nucleic acid (PNA) duplex at 1.7 A resolution. Nat Struct Biol 1997; 4:98–101.PubMedCrossRefGoogle Scholar
  138. 138.
    Bastide L, Boehmer PE, Villani G et al. Inhibition of a DNA-helicase by peptide nucleic acids. Nucleic Acids Res 1999; 27:551–4.PubMedCrossRefGoogle Scholar
  139. 139.
    Boehmer PE, Lehman IR. Herpes simplex virus DNA replication. Annu Rev Biochem 1997; 66:347–84.PubMedCrossRefGoogle Scholar
  140. 140.
    Kurg R, Langel U, Ustav M. Inhibition of the bovine papillomavirus E2 protein activity by pep-tide nucleic acid. Virus Res 2000; 66:39–50.PubMedCrossRefGoogle Scholar
  141. 141.
    Spalholz BA, Yang YC, Howley PM. Transactivation of a bovine papilloma virus transcriptional regulatory element by the E2 gene product. Cell 1985; 42:183–91.PubMedCrossRefGoogle Scholar
  142. 142.
    Tackett AJ, Wei L, Cameron CE et al. Unwinding of nucleic acids by HCV NS3 helicase is sensitive to the structure of the duplex. Nucleic Acids Res 2001; 29:565–72.PubMedCrossRefGoogle Scholar
  143. 143.
    Stock RP, Olvera A, Sanchez R et al. Inhibition of gene expression in Entamoeba histolytica with antisense peptide nucleic acid oligomers. Nat Biotechnol 2001; 19:231–4.PubMedCrossRefGoogle Scholar
  144. 144.
    Good L, Nielsen PE. Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. Nat Biotechnol 1998; 16:355–8.PubMedCrossRefGoogle Scholar
  145. 145.
    Good L, Awasthi SK, Dryselius R et al. Bactericidal antisense effects of peptide-PNA conjugates. Nat Biotechnol 2001; 19:360–4.PubMedCrossRefGoogle Scholar
  146. 146.
    Pooga M, Hallbrink M, Zorko M et al. Cell penetration by transportan. Faseb J 1998; 12:67–77.PubMedGoogle Scholar
  147. 147.
    Pooga M, Lindgren M, Hallbrink M et al. Galanin-based peptides, galparan and transportan, with receptor-dependent and independent activities. Ann N Y Acad Sci 1998; 863:450–3.PubMedCrossRefGoogle Scholar
  148. 148.
    Derossi D, Calvet S, Trembleau A et al. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 1996; 271:18188–93.PubMedCrossRefGoogle Scholar
  149. 149.
    Villa R, Folini M, Lualdi S et al. Inhibition of telomerase activity by a cell-penetrating peptide nucleic acid construct in human melanoma cells. FEBS Lett 2000; 473:241–8.PubMedCrossRefGoogle Scholar
  150. 150.
    Feng J, Funk WD, Wang SS et al. The RNA component of human telomerase. Science 1995; 269:1236–41.PubMedCrossRefGoogle Scholar
  151. 151.
    Brown D, Kogan S, Lagasse E et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997; 94:2551–6.PubMedCrossRefGoogle Scholar
  152. 152.
    Hamilton SE, Simmons CG, Kathiriya IS et al. Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chem Biol 1999; 6:343–51.PubMedCrossRefGoogle Scholar
  153. 153.
    Kalderon D, Roberts BL, Richardson WD et al. A short amino acid sequence able to specify nuclear location. Cell 1984; 39:499–509.PubMedCrossRefGoogle Scholar
  154. 154.
    Cutrona G, Carpaneto EM, Ulivi M et al. Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal. Nat Biotechnol 2000; 18:300–3.PubMedCrossRefGoogle Scholar
  155. 155.
    Boffa LC, Scarfi S, Mariani MR et al. Dihydrotestosterone as a selective cellular/nuclear localization vector for anti-gene peptide nucleic acid in prostatic carcinoma cells. Cancer Res 2000; 60:2258–62.PubMedGoogle Scholar
  156. 156.
    Basu S, Wickstrom E. Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake. Bioconjug Chem 1997; 8:481–8.PubMedCrossRefGoogle Scholar
  157. 157.
    Penichet ML, Kang YS, Pardridge WM et al. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: Initial applications in anti-HIV antisense drug delivery to the brain. J Immunol 1999; 163:4421–6.PubMedGoogle Scholar
  158. 158.
    Pardridge WM, Boado RJ, Kang YS. Vector-mediated delivery of a polyamide (“peptide”) nucleic acid analogue through the blood-brain barrier in vivo. Proc Natl Acad Sci USA 1995; 92:5592–6.PubMedCrossRefGoogle Scholar
  159. 159.
    Rezaei K, Xu IS, Wu WP et al. Intrathecal administration of PNA targeting galanin receptor reduces galanin-mediated inhibitory effect in the rat spinal cord. Neuroreport 2001; 12:317–20.PubMedCrossRefGoogle Scholar
  160. 160.
    BarreSinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a pa-tient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220:868–71.CrossRefGoogle Scholar
  161. 161.
    Gallo RC, Sarin PS, Gelmann EP et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983; 220:865–7.PubMedCrossRefGoogle Scholar
  162. 162.
    Gao F, Bailes E, Robertson DL et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999; 397:436–41.PubMedCrossRefGoogle Scholar
  163. 163.
    Dalgleish AG, Beverley PC, Clapham PR et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984; 312:763–7.PubMedCrossRefGoogle Scholar
  164. 164.
    Klatzmann D, Champagne E, Chamaret S et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984; 312:767–8.PubMedCrossRefGoogle Scholar
  165. 165.
    Alkhatib G, Combadiere C, Broder CC et al. CC CKR5: A RANTES, MlP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955–8.PubMedCrossRefGoogle Scholar
  166. 166.
    Bleul CC, Farzan M, Choe H et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996; 382:829–33.PubMedCrossRefGoogle Scholar
  167. 167.
    Deng H, Liu R, Ellmeier W et al. Identification of a major coreceptor for primary isolates of HIV-1 [see comments]. Nature 1996; 381:661–6.PubMedCrossRefGoogle Scholar
  168. 168.
    Dragic T, Litwin V, Allaway GP et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 [see comments]. Nature 1996; 381:667–73.PubMedCrossRefGoogle Scholar
  169. 169.
    Feng Y, Broder CC, Kennedy PE et al. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor [see comments]. Science 1996; 272:872–7.PubMedCrossRefGoogle Scholar
  170. 170.
    Tang H, Kuhen KL, Wong-Staal F. Lentivirus replication and regulation. Annu Rev Genet 1999; 33:133–70.PubMedCrossRefGoogle Scholar
  171. 171.
    McCune JM. The dynamics of CD4+ T-cell depletion in HIV disease. Nature 2001; 410:974–9.PubMedCrossRefGoogle Scholar
  172. 172.
    O’Brien SJ, Moore JP. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev 2000; 177:99–111.PubMedCrossRefGoogle Scholar

Copyright information

© and Kluwer Academic / Plenum Publishers 2006

Authors and Affiliations

  • Shizuko Sei
    • 1
  1. 1.Laboratory of Antiviral Drug Mechanisms Screening Technologies Branch Developmental Therapeutics Program SAIC-FrederickNCI-FrederickFrederickUSA

Personalised recommendations